Citations

Clear

5 citation(s) found for "Breitfeld, P P".

Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience
Breitfeld, P P, Anderson, J R , Rodeberg, David A. , Qualman, S., Wolden, S., Meyer, William H. , Kao, Simon C.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 8513-8513

10.1200/jco.2004.22.90140.8513 Get It

Survival After Relapse in Children and Adolescents With Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Study Group
Pappo, Alberto S. , Anderson, James R. , Crist, William M., Wharam, Moody D., Breitfeld, P P, Hawkins, Douglas S. , Raney, R. Beverly, Womer, Richard B. , Parham, David M. , Qualman, Steven J., Grier, Holcombe E. , Hawkins, Douglas S

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 17 | Issue: 11 | Pages: 3487-3493

10.1200/jco.1999.17.11.3487 | PMID 10550146 Get It

BACKGROUND: Despite advances in therapy, nearly 30% of children with rhabdomyosarcoma experience progressive or relapsed disease, which is often fatal. PATIENTS AND METHODS: To facilitate the development of a retrieval therapy protocol, we studied potential risk factors that were predictive of survival after first relapse in 605 children who were enrolled onto three consecutive Intergroup Rhabdomyosarcoma Study Group protocols. RESULTS: The median survival time from first recurrence was 0.8 years; the estimated percentage of patients who survived 5 years from first recurrence was 17% ± 2% (mean ± SD). Univariate analysis showed that tumor histology was an important predictor of 5-year survival (P < .001): the 5-year survival rate was 64% for patients with botryoid tumors (n = 19), 26% for patients with embryonal tumors (n = 313), and 5% for patients with alveolar or undifferentiated sarcoma (n = 273). Further analysis identified prognostic factors within histologic subtypes (P < .001). For patients with embryonal tumors, the estimated 5-year survival rate was 52% for patients who initially presented with stage 1 or group I disease, 20% for those with stage 2/3 or group II/III disease, and 12% for those with group IV disease. For patients with stage 1/group I disease, estimated 5-year survival rates were higher for patients with local (72%) or regional (50%) recurrence than for those with distant (30%) recurrence. Among patients with alveolar or undifferentiated sarcoma, only the disease group predicted outcome: the 5-year survival estimate was 40% for group I versus 3% for groups II through IV. We identified a “favorable risk” group (approximately 20% of patients) whose 5-year estimated survival rate was near 50%; for all other patients, the estimated survival was near 10%. CONCLUSION: This analysis demonstrates that the probability of 5-year survival after relapse for rhabdomyosarcoma is dependent on several factors at the time of initial diagnosis, including histologic subtype, disease group, and stage. These findings will form the basis of a multi-institutional risk-adapted relapse protocol for childhood rhabdomyosarcoma.
Age Is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin, and Cyclophosphamide
Arndt, Carola, Hawkins, Douglas S. , Anderson, J R , Breitfeld, P P, Womer, Richard B. , Meyer, William H. , Hawkins, Douglas S

Mayo Clinic

Journal of Clinical Oncology | May 13, 2004 | Volume: 22 | Issue: 10 | Pages: 1894-1901

10.1200/jco.2004.08.075 | PMID 15143082 Get It

Purpose To evaluate the spectrum of and determine the risk factors for the development of liver toxicity (hepatopathy) after therapy with vincristine, dactinomycin, and cyclophosphamide (VAC) for rhabdomyosarcoma in children and adolescents. Patients and Methods We prospectively captured all events of hepatopathy occurring on the ongoing Children's Oncology Group intermediate risk protocol, D9803, for children with rhabdomyosarcoma. Patients enrolled onto this trial were randomly assigned to receive either VAC alone or VAC alternating with vincristine, topotecan, and cyclophosphamide. In addition, we reviewed the toxicity database and requested additional information for all patients with elevated bilirubin or transaminase levels. Risk factors were analyzed. Results Of 339 patients enrolled through August 2002, 18 developed hepatopathy. All events were captured by mandated toxicity reporting and filing of MedWatch forms, with no additional cases found after the additional search of the database. Four children died after developing this toxicity. All cases occurred after cycles of VAC (n = 16) or vincristine and cyclophosphamide with concomitant abdominal radiotherapy (n = 2). The onset of hepatopathy was 5 to 16 days from the start of a treatment cycle. For the 89 patients under 36 months of age, the risk of hepatopathy was 15%, with two deaths. For the 239 children 3 years of age or older, the risk for hepatopathy was 4%, with two deaths. Conclusion The greatest risk factor for development of hepatopathy after VAC therapy was age. Dose modifications for younger children receiving VAC therapy are recommended.
DOES BLADDER PRESERVATION (AS A SURGICAL PRINCIPLE) LEAD TO RETAINING BLADDER FUNCTION IN BLADDER/PROSTATE RHABDOMYOSARCOMA? RESULTS FROM INTERGROUP RHABDOMYOSARCOMA STUDY IV
Arndt, Carola, Rodeberg, David A. , Breitfeld, Philip P., Raney, R. Beverly, Ullrich, Fred , Donaldson, Sarah S. , Donaldson, Sarah S

Mayo Clinic

Journal of Urology | May 3, 2004 | Volume: 171 | Issue: 6 Part 1 | Pages: 2396-2403

10.1097/01.ju.0000127752.41749.a4 | PMID 15126860 Get It

Clinicopathologic Study of Ectomesenchymomas from Intergroup Rhabdomyosarcoma Study Groups III and IV
Boué, Daniel R. , Parham, David M. , Crist, William M., Qualman, Stephen J., Office, from the Intergroup Rhabdomyosarcoma Study Group (IRSG) representing the Children's Cancer Group, the Pediatric Oncology Group,, Anderson, James R., Breitfeld, Richard J., Breneman, John C. , Bridge, Julia A. , Brown, Kenneth L. , Grier, Holcombe E. , Houghton, Peter J. , Link, Michael P., Lobe, Thom L., Maurer, Harold M., Meyer, William H. , Michalski, Jeff M. , Murphy, Sharon, Raney, R. Beverly, Robison, Leslie, Skapek, Stephen X. , Teot, Lisa A., Vietti, Teresa J., Walterhouse, David , Wharam, Mondy, Wiener, Eugene S. , Womer, Richard B. , Webber, Bruce L. , Office, from the Intergroup Rhabdomyosarcoma Study Group (IRSG) representing the Children's Cancer Group, the Pediatric Oncology Group, and the Intergroup Rhabdomyosarcoma Statistical, Anderson, James R., Donaldson, Sarah S. , Hawkins, Douglas S. , Paidas, Charles N. , Pappo, Alberto S. , Sandler, Eric , Smith, Lynn , Sorensen, Poul H. , Spunt, Sheri L. , Triche, Timothy J. , Wolden, Suzanne L.

Mayo Clinic

Pediatric and Developmental Pathology | July 25, 2002 | Volume: 3 | Issue: 3 | Pages: 290-300

10.1007/s100249910039 | PMID 10742419 Get It

Ectomesenchymomas (EM) are rare malignant neoplasms usually consisting of rhabdomyosarcoma (RMS) with a neural component. Only 21 cases have been previously reported. Here we extend the clinicopathologic spectrum of EM by describing our findings in 15 cases. Only 5 patients were infants; 10 were ≤3 years old and 5 were ≥6 years old. No male predilection was observed; 7 were female. The originating institutional diagnoses were; RMS (12), undifferentiated sarcoma (1), or EM (2), suggesting underdiagnosis of this entity. The primary tumor sites included external genital (5), pelvis/abdomen (6), head and neck (3), and extremity (1). The size of the primary neoplasm was usually ≥5 cm at diagnosis but dissemination only occurred in a minority. Local infiltration was not uncommon. These neoplasms were typically multilobate, thinly encapsulated, hemorrhagic, and necrotic. Light microscopic features were highly variable, but embryonal RMS with scattered or clustered ganglion cells, often in lacunae, was characteristic. In some cases, primitive neuroblastic or neuroectodermal areas were found and/or a component of alveolar RMS was seen. Focal anaplasia was occasionally observed. Mitotic activity appears higher than previously appreciated and some necrosis was invariably present. Electron microscopy was performed in 11 cases, which confirmed skeletal muscle ± neural differentiation. Cytogenetic studies performed in five cases revealed no specific abnormality. Monoclonal neuron-specific enolase was the best marker of ganglion cells and primitive neural elements. MIC-2 (CD99) membrane expression was not definitively present in any of the six cases examined. A number of the above parameters appear to be of some prognostic significance, but overall, these neoplasms appear to have a similar outcome as would be predicted for their RMS element alone (exclusive of any neural component), with respect to the RMS subtype, age of the patient, and anatomic location of the neoplasm.